---
title: "Citi Sticks to Their Buy Rating for Wuxi Biologics (Cayman) (WXIBF)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/282760874.md"
description: "Citi has reaffirmed its Buy rating for Wuxi Biologics (Cayman) with a price target of HK$42.00, while the stock closed at HK$35.28. The analyst consensus is a Strong Buy with an average target of HK$45.96, indicating a potential upside of 30.28%. Additionally, Morgan Stanley also maintains a Buy rating with a target of HK$50.00."
datetime: "2026-04-15T00:46:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/282760874.md)
  - [en](https://longbridge.com/en/news/282760874.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/282760874.md)
---

# Citi Sticks to Their Buy Rating for Wuxi Biologics (Cayman) (WXIBF)

In a report released on April 13, from Citi maintained a Buy rating on Wuxi Biologics (Cayman), with a price target of HK$42.00. The company’s shares closed last Wednesday at HK$35.28.

### Claim 30% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Currently, the analyst consensus on Wuxi Biologics (Cayman) is a Strong Buy with an average price target of HK$45.96, representing a 30.28% upside. In a report released on April 7, Morgan Stanley also maintained a Buy rating on the stock with a HK$50.00 price target.

### Related Stocks

- [WXXWY.US](https://longbridge.com/en/quote/WXXWY.US.md)
- [02269.HK](https://longbridge.com/en/quote/02269.HK.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)

## Related News & Research

- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [LifeSci Capital Sticks to Their Buy Rating for Tenax Therapeutics (TENX)](https://longbridge.com/en/news/286648286.md)
- [Leerink Partners Sticks to Their Buy Rating for Ibio (IBIO)](https://longbridge.com/en/news/286588262.md)
- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)